Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
• Helus Pharma reported its financial results for the first quarter of fiscal 2027, ending June 30, 2026, alongside key business updates. • The company appointed former Intra-Cellular Therapies President Michael Halstead as CEO to oversee late-stage development and future commercialization efforts. • Enrollment has been completed for the Phase 3 APPROACH pivotal study evaluating HLP003 for the treatment of Major Depressive Disorder (MDD).
investingnews.com


